Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01157351 · ClinicalTrials.gov registry record · Phase 4
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
A Phase 4 study, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
- 450
- Enrollment target
NCT01157351 is a Phase 4 study that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 450 participants.
The verdict
NCT01157351, a Phase 4 study, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 450 participants
- Enrollment target
Study Summary
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated.
Interventions
- DRUG risperidone
- DRUG aripiprazole
- DRUG paliperidone
- DRUG haloperidole
- DRUG perphenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01157351
The ClinicalTrials.gov registry entry for NCT01157351 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which risperidone is the first listed.
NCT01157351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01157351 about?
NCT01157351 is a clinical study titled "15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated". The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated.
What is the current status of trial NCT01157351?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 450 participants. The study started on 2010-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01157351?
The interventions under investigation include: risperidone (DRUG), aripiprazole (DRUG), paliperidone (DRUG), haloperidole (DRUG), perphenazine (DRUG).
Who is sponsoring clinical trial NCT01157351?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.